HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Charis Papavassilis Selected Research

Biological Therapy

1/2018Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
9/2017Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Charis Papavassilis Research Topics

Disease

16Psoriasis (Pustulosis Palmaris et Plantaris)
10/2023 - 09/2013
2Infections
07/2016 - 07/2014
1Nasopharyngitis
10/2016
1Candidiasis (Moniliasis)
07/2016
1Neoplasms (Cancer)
07/2016
1Pruritus (Itching)
04/2016
1Pain (Aches)
04/2016
1Psoriatic Arthritis
08/2015

Drug/Important Bio-Agent (IBA)

14secukinumabIBA
10/2023 - 09/2013
8Monoclonal AntibodiesIBA
10/2023 - 07/2014
7Interleukin-17 (Interleukin 17)IBA
10/2023 - 07/2014
4Immunoglobulin A (IgA)IBA
10/2016 - 12/2014
3Etanercept (Enbrel)FDA Link
07/2016 - 07/2014
2CytokinesIBA
12/2020 - 12/2014
1Biomarkers (Surrogate Marker)IBA
12/2020
1Prostaglandins AIBA
02/2015

Therapy/Procedure

2Biological Therapy
01/2018 - 09/2017
2Therapeutics
08/2017 - 04/2016
1Self Administration (Administration, Self)
10/2016
1Phototherapy (Light Therapy)
04/2016
1Retreatment
07/2015